No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients
Open Access
- 11 December 2009
- journal article
- Published by Frontiers Media SA in Transplant International
- Vol. 23 (6), 594-601
- https://doi.org/10.1111/j.1432-2277.2009.01025.x
Abstract
Persistence of hepatitis C virus (HCV) in patients who cleared HCV is still debated. Occult HCV infection is described as the presence of detectable HCV RNA in liver or peripheral blood mononuclear cells (PBMCs) of patients with undetectable plasma HCV-RNA by conventional PCR assays. We have assessed the persistence of HCV in 26 kidney-transplant patients, followed up for 10.5 years (range 2–16), after HCV elimination while on hemodialysis. If HCV really did persist, arising out of the loss of immune control caused by institution of the regimen of immunosuppressive drugs after kidney transplantation, HCV reactivation would have taken place. Their immunosuppression relied on calcineurin inhibitors (100%), and/or steroids (62%), and/or antimetabolites (94%). An induction therapy, given to 22 patients, relied on rabbit antithymocyte globulin (59%) or anti-IL2-receptor blockers (32%). All patients had undetectable HCV RNA as ascertained by several conventional tests. At the last follow-up, no residual HCV RNA was detected in the five liver biopsies, the 26 plasma, and in the 37 nonstimulated and 24 stimulated PBMCs tested with an ultrasensitive RT-PCR assay (detection limit, 2 IU/ml). No biochemical or virologic relapse was seen during follow-up. The absence of HCV relapse in formerly HCV-infected immunocompromised patients suggests the complete eradication of HCV after its elimination while on dialysis.Keywords
This publication has 39 references indexed in Scilit:
- Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitroHepatology, 2008
- Occult Hepatitis C Virus Infection among Hemodialysis PatientsJournal of the American Society of Nephrology, 2008
- Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patientsHepatology, 2008
- Hepatitis C virus, an important risk factor for tuberculosis in immunocompromised: experience with kidney transplantationTransplant International, 2008
- Persistence of Hepatitis C Virus in Peripheral Blood Mononuclear Cells of Sustained Viral Responders to Pegylated Interferon and Ribavirin TherapyDigestive Diseases and Sciences, 2008
- Ultracentrifugation of Serum Samples Allows Detection of Hepatitis C Virus RNA in Patients with Occult Hepatitis CJournal of Virology, 2007
- Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPSKidney International, 2004
- The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre studyNephrology Dialysis Transplantation, 2004
- A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infectionLiver Transplantation, 2004
- TREATMENT OF CHRONIC HEPATITIS C WITH RECOMBINANT INTERFERON ALPHA IN KIDNEY TRANSPLANT RECIPIENTSTransplantation, 1995